Allergies News and Research

Latest Allergies News and Research

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Surgeons perform robotic gall bladder surgery more safely

A green fluorescent dye is helping surgeons at the University of Illinois Hospital & Health Sciences System perform robotic gall bladder surgery more safely.

8 May 2014

NIH-funded study in tanzanian infants tracked risk of severe malaria over time

Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.

8 May 2014

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot.

8 May 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.

6 May 2014

Johns Hopkins researchers awarded NIH contract to launch new center to track influenza viruses

The National Institutes of Health has awarded a contract to researchers at The Johns Hopkins University to launch a new center devoted to developing innovative ways to identify and track influenza viruses worldwide.

6 May 2014

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

6 May 2014

New research reveals that eczema may lower skin cancer risk

Eczema caused by defects in the skin could reduce the risk of developing skin cancer, according to new research by King's College London. The immune response triggered by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.

6 May 2014

Tens of thousands of premature deaths could be prevented each year

Heart disease, cancer, chronic lower respiratory diseases, stroke, and unintentional injuries cause nearly 900,000 premature deaths in the US each year. A recent study showed that 20–40% of deaths from each of these causes could be prevented.

2 May 2014

Study: Asthma is associated with reduced bone mineral density

Some of the 26 million Americans with asthma may also be prone to bone loss. According to a study published today in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology, there seems to be association between asthma and a decrease in bone mineral density.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Researchers develop wireless bug sensor to help farmers protect crops from insect damage

University of California, Riverside researchers have created a method that can classify different species of insects with up to 99 percent accuracy, a development that could help farmers protect their crops from insect damage and limit the spread of insect-borne diseases, such as malaria and Dengue fever.

30 Apr 2014

Royal Solutions 3.0 gets ONC HIT 2014 Edition Modular EHR certification

Royal Solutions Group's, Royal Solutions 3.0 has achieved ONC HIT 2014 Edition Modular EHR certification, which designates that the software is capable of supporting eligible providers with meeting the Stage 1 and Stage 2 Meaningful Use measures required to qualify for funding under the American Recovery and Reinvestment Act.

29 Apr 2014

Researchers develop animal model of human hantavirus pulmonary syndrome

National Institutes of Health (NIH) researchers have developed an animal model of human hantavirus pulmonary syndrome (HPS) in rhesus macaques, an advance that may lead to treatments, vaccines and improved methods of diagnosing the disease.

29 Apr 2014

Anaphylaxis Campaign's special conference to explore issues in allergy care

This special conference for our 20th Anniversary year will focus on providing a full and comprehensive round up of past, present and emerging themes and trends in allergy, care and management. The conference is free to all our Healthcare Professional Members and we are expecting over 70 clinicians in the field of allergy to attend.

29 Apr 2014

Mauna Kea receives regulatory approval in Japan for Cellvizio flagship product

Mauna Kea Technologies, leader in the optical biopsy market, announced today it received regulatory approval in Japan for the company's Cellvizio flagship product.

28 Apr 2014

H2Ocean launches Extreme Tattoo Aftercare Kit

H2Ocean, a leader in developing natural health care products using patented sea salt formulas, is proud to announce the launch of their coveted Extreme Tattoo Aftercare Kit in 5,179 Walgreens stores Nationwide found in the First Aid Section.

26 Apr 2014

NIH award reflects urgency of overcoming infections that resist drug treatment

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.

26 Apr 2014

NIAMS scientific director to receive 2014 Ross Prize in Molecular Medicine

John J. O'Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has been named the 2014 recipient of the Ross Prize in Molecular Medicine, conferred by the Feinstein Institute's peer-reviewed, open-access journal Molecular Medicine.

25 Apr 2014

Reduced exposure to microbes triggers chronic inflammation

The greater prevalence of asthma, allergies and other chronic inflammatory disorders among people of lower socioeconomic status might be due in part to their reduced exposure to the microbes that thrive in rural environments, according to a new scientific paper.

25 Apr 2014